Akèy › Kansè nan tete › Montana
Etid klinik pou Kansè nan tete nan Montana
13 etid pou Kansè nan tete ap chèche patisipan nan sit nan Montana.
Vil nan Montana
Tèks ofisyèl etid la (Anglè)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Intermountain Healthcare, Billings
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Oct 2, 2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Community Hospital of Anaconda, Anaconda
- Billings Clinic Cancer Center, Billings
- Bozeman Health Deaconess Hospital, Bozeman
- ak 7 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- St. Vincent Regional Hospital - Cancer Centers of Montana, Billings
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07007559Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003), Billings
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06797635A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- St. Vincent Frontier Cancer Center (SVFCC) - Billings (Frontier Cancer Center and Blood Institute), Billings
Ap rekriteFaz 1
Laj 18 a 55 · Fanm · Mizajou Sep 9, 2026 · NCT07310420Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Community Hospital of Anaconda, Anaconda
- Billings Clinic Cancer Center, Billings
- Saint Vincent Frontier Cancer Center, Billings
- ak 10 plis
Ap rekriteFaz 3
Laj 18 a 60 · Fanm · Mizajou Sep 2, 2026 · NCT05879926Integrated Cancer Repository for Cancer Research
- Bozeman Health Deaconess Hospital, Bozeman
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- SCL Health - Cancer Centers of Montana, Billings
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou May 18, 2026 · NCT06757634De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- Billings Clinic Cancer Center, Billings
- Bozeman Health Deaconess Hospital, Bozeman
- Benefis Sletten Cancer Institute, Great Falls
- ak 1 plis
Ap rekriteFaz 3
Laj 50 a 70 · Tout sèks · Mizajou Apr 23, 2026 · NCT04852887Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Community Hospital of Anaconda, Anaconda
- Billings Clinic Cancer Center, Billings
- Montana Cancer Consortium NCORP, Billings
- ak 5 plis
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Mar 17, 2026 · NCT06418204Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors
- University of Montana, Missoula
Ap rekriteFaz 2
Laj 18 a 89 · Tout sèks · Mizajou Feb 5, 2026 · NCT07001241SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Billings
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Benefis Healthcare- Sletten Cancer Institute, Great Falls
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 8, 2025 · NCT03418961Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.